o2h has a track record of investing in emerging biotech, small molecule and frontier life science, tech & digital health start-ups.
Exonate is a biopharmaceutical company focussed on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.
From initial concept to the delivery of candidate drugs – we’re a drug discovery company specialising in cutting-edge cancer treatment.
PhoreMost® has developed a next-generation phenotypic screening platform called ‘SITESEEKER®’ to identify the best new targets for future therapy, and crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancer and other unmet diseases, where treatment options are currently severely limited.
Talisman Therapeutics, a spinout from the University of Cambridge, is a stem cell research and development company committed to revolutionising the discovery of treatments for Alzheimer’s disease.
Science-led ambitious start up focused on the development of antibacterial compounds with novel mechanisms of action against drug resistant organisms.
Absynth Biologics discovers and develops vaccines and antibodies to prevent and treat bacterial infections; based on a platform for identifying novel protein antigen targets that harness the immune system.
Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.
LaborVoices provides global brands and their supply chains what has been missing: an early warning system based on direct feedback from workers, by repeatedly polling workers through their mobile phones.
IOTA Pharmaceuticals has been established to bring you the tools and technologies for Fragment-based Drug Discovery(FBDD) and High-content Screening(HCS).
Small Pharma is forging a new path in pharmaceutical development by bridging the gap between academia and industry.
Oxford Drug Design (formerly InhibOx) is a biotechnology company focused on internal drug discovery. The lead antibacterial programme has identified compounds with the potential to be developed into therapies for Gram-negative bacterial infections, including against strains resistant to multiple current antibacterial drug classes.
A UK-based leading formulation technology company delivering superior biopharmaceuticals via the innovative reformulation of proteins and peptides.
The Repositive platform enables researchers to browse through multiple repositories for the human genomic data they need to power their research.
Privitar facilitates broader use of data while adopting an uncompromising approach to protecting confidential information.
Heartfelt Technologies exists to help patients, their families, carers and doctors, to reduce hospital re-admission rates from congestive heart failure de-compensation.
Stemnovate at Cambridge, UK are developing a ‘liver on a chip’ system supported by a $1m Innovate UK award. The platform is based on cutting edge stem cell and micro engineering platform technologies at University of Edinburgh and Cambridge University.
In January, Exonate, one of o2h venture's investement, was approached by the British Business Bank to feature in a series of videos to highlight their Business Finance Guide. The British Business Bank and Angel Co Fund have provided valuable funding and support to Exonate and our investment was highlighted an excellent case study to promote the banks work. Sunil Shah, CEO, o2h Ventures and Peter Cowley of Angel Co Fund were invited to take part and spent time being filmed in The Bradfield Centre in the Cambridge Science park. Watch the video here Read the full article
The quest to positively benefit the lives of patients in the world of drug discovery means finding novel therapeutics for unmet medical needs. The biotech and pharma companies have been increasingly resorting to external innovation to supplement their pipeline of ideas and turbocharge their research-based businesses with enterprising partners with complementary ideas, capabilities and services. It is therefore hardly surprising that the top medicinal chemists working in both large and small companies have multiple partners across different continents and time-zones. To deliver these iterative discovery projects often entails detailed co-ordination of inter-related activities and extensive multi-tasking. Project management is the hub that allows these complex matrices of networks to communicate and for the project to successfully advance. In today’s fast paced and technologically advanced digital world, providing the project manager the right tools to make informed decisions is key to successful delivery. o2h Discovery’s innovative app Chemistry in the Cloud TM builds upon the latest advances in secure cloud-based mobile technology and integrates project management of external drug discovery programs. The app enables communication between the various scientific stakeholders essential to successful project advancement leading to faster decision making. It negates the onerous tasks of weeding out critical information that is required to take a complex decision by extracting the information from large data intensive reports and databases. These crucial decision points are now just a ‘tap/swipe-of-the-finger’ in the Chemistry in the CloudTM app so that they can speedily execute tasks anytime, anywhere. The communication covering a gamut of research activities in relation to process of research now truly happens in 24/7 real-time. o2h announced a worldwide launch and first live demonstration of our revolutionary project management app – Chemistry in the Cloud TM on 10th September 2017 at the 19th RSC/SCI Cambridge medicinal chemistry conference to some of world’s top scientists. The app’s full suite of project management tools is available exclusively to live project collaborators and a lighter version is open for researchers looking for a quote for the synthesis of small molecules. https://www.linkedin.com/in/sunil-shah-4bb225/detail/recent-activity/shares/ Nilesh Dagia (firstname.lastname@example.org) is the COO @ o2h Discovery
Fast decision making, anytime, anywhere… For More Information - Press Release - Chemistry in the cloud
O2h Discovery: Chemistry in the Cloud™ - The World's First App To Project Manage Drug Discovery - https://t.co/LP0dpstmFI
RT @OxDrugDes: Grace presented her poster and Michael gave a talk at #aars2017 yesterday! Track them down if you want to find out more abou…
@o2hventures are @TheMilnerInst #MilnerSymp17 today engaging with @cambridgeuniv academics seeking collaborative opportunities.
O2h Discovery: Proud sponsors of the19th RSC/SCI Medicinal Chemistry Symposium; we will be lifting our skirt with our latest innovation!
RT @Anastasiya_B94: Thanks Frances Doherty and @UKBAngels for hosting me & @richardmuirhead tonigh! @openoceanvc Great evening https://t. …
RT @ExonateUK: Best Investment in Life Sciences Ones to watch award at the @UKBAngels awards 2017 #UKBAAAwards @o2hventures https://t.co/4q …
Sharing a recent article that I wrote for the Milner Institute https://t.co/HRlqvrHp4Z by @o2hventures on @LinkedIn
@TalentAdvocates presenting at the o2h team day! https://t.co/1pcjvrj7i8